{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:27:29Z","timestamp":1784140049239,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"DOI":"10.7759\/cureus.17573","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T16:06:25Z","timestamp":1630339585000},"source":"Crossref","is-referenced-by-count":5,"title":["Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers"],"prefix":"10.7759","author":[{"given":"Kabeer","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed R","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Deonarine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surujpal","family":"Teelucksingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0650","article-title":"Drug-induced pruritus: a review","volume":"89","author":"Reich A","year":"2009","unstructured":"Reich A, St\u00e4nder S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol. 2009, 89:236-44. 10.2340\/00015555-0650","journal-title":"Acta Derm Venereol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0662","article-title":"Epidemiology of itch: adding to the burden of skin morbidity","volume":"89","author":"Weisshaar E","year":"2009","unstructured":"Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol. 2009, 89:339-50. 10.2340\/00015555-0662","journal-title":"Acta Derm Venereol"},{"key":"ref3","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review","volume":"10","author":"Raj H","year":"2019","unstructured":"Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes. 2019, 10:114-32. 10.4239\/wjd.v10.i2.114","journal-title":"World J Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2016.142","article-title":"Dapagliflozin-induced acute-on-chronic liver injury","volume":"3","author":"Levine JA","year":"2016","unstructured":"Levine JA, Ann Lo A, Wallia A, Rogers M, VanWagner LB. Dapagliflozin-induced acute-on-chronic liver injury. ACG Case Rep J. 2016, 3:e169. 10.14309\/crj.2016.142","journal-title":"ACG Case Rep J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch J","year":"2006","unstructured":"Bosch J, Yusuf S, Gerstein HC, et al.. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006, 355:1551-62. 10.1056\/NEJMoa065061","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami D","year":"2017","unstructured":"Kawanami D, Matoba K, Takeda Y, et al.. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017, 18:1083. 10.3390\/ijms18051083","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney DZ","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al.. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014, 86:1057-8. 10.1038\/ki.2014.246","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311666160405110515","article-title":"Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction?","volume":"13","author":"Vasapollo P","year":"2018","unstructured":"Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction?. Curr Drug Saf. 2018, 13:38-40. 10.2174\/1574886311666160405110515","journal-title":"Curr Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe D","year":"2015","unstructured":"Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015, 14:795-800. 10.1517\/14740338.2015.1034105","journal-title":"Expert Opin Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0438-3","article-title":"Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis","volume":"36","author":"Mellander A","year":"2016","unstructured":"Mellander A, Billger M, Johnsson E, Tr\u00e4ff AK, Yoshida S, Johnsson K. Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis. Clin Drug Investig. 2016, 36:925-33. 10.1007\/s40261-016-0438-3","journal-title":"Clin Drug Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12910","article-title":"Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"10","author":"Yabe D","year":"2019","unstructured":"Yabe D, Yasui A, Ji L, et al.. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. J Diabetes Investig. 2019, 10:418-28. 10.1111\/jdi.12910","journal-title":"J Diabetes Investig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: a\u00a0global analysis of international spontaneous reporting systems","volume":"27","author":"Raschi E","year":"2017","unstructured":"Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, Poluzzi E. Adverse events with sodium-glucose co-transporter-2 inhibitors: a\u00a0global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2017, 27:1098-107. 10.1016\/j.numecd.2017.10.008","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68893-sodium-glucose-co-transporter-2-inhibitor-induced-pruritus-itching-for-answers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:45Z","timestamp":1707507285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68893-sodium-glucose-co-transporter-2-inhibitor-induced-pruritus-itching-for-answers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.17573","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,30]]}}}